Idarubicina Sandoz (Idarubicin Hydrochloride)

Idarubicin is an anthracycline chemotherapy agent used primarily in the management of acute myeloid leukemia.

• Acute myeloid leukemia (AML): induces remission by killing rapidly proliferating leukemic blasts.
• Relapsed or refractory AML: offers a therapeutic option to achieve disease control when prior regimens have failed.
• High‑risk AML (including certain cytogenetic subtypes): used as part of intensive induction protocols to improve response rates.
• AML in patients unsuitable for standard anthracyclines: provides an alternative with similar efficacy.

• Idarubicin intercalates between DNA base pairs, disrupting the double‑helix structure and preventing replication. It also stabilizes the DNA‑topoisomerase II complex, inhibiting the enzyme’s ability to reseal DNA strands after cleavage, leading to accumulation of double‑strand breaks and triggering apoptosis in rapidly dividing malignant cells. These actions are dose‑dependent and result in cytotoxicity preferentially in proliferating hematopoietic cells while sparing most quiescent normal tissues at therapeutic concentrations.

Idarubicin, like other anthracyclines, is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea and vomiting: gastrointestinal upset commonly reported during treatment.
• Myelosuppression: decreased blood cell counts leading to anemia, neutropenia, and thrombocytopenia.
• Alopecia: temporary hair loss affecting scalp and body hair.
• Mucositis: inflammation and ulceration of the oral mucosa.
• Fatigue: persistent tiredness affecting daily activities.

Serious or Rare Side Effects

• Cardiotoxicity: irreversible damage to heart muscle that may lead to heart failure.
• Severe neutropenic infection: life‑threatening infections due to profound neutropenia.
• Acute hypersensitivity reactions: anaphylaxis or severe infusion‑related reactions.
• Secondary leukemia: rare development of therapy‑related myeloid neoplasm.
• Acute tumor lysis syndrome: rapid release of intracellular contents causing metabolic disturbances.
• Pulmonary toxicity: interstitial pneumonitis or fibrosis in rare cases.

When using Idarubicina Sandoz, clinicians should observe several precautionary measures to minimize risk.

• Cardiac assessment: perform baseline and periodic echocardiograms to monitor left ventricular function.
• Hematologic monitoring: conduct regular complete blood counts to detect myelosuppression early.
• Concomitant nephrotoxic drugs: avoid or adjust dosing when used with other agents that impair renal function.
• Pregnancy and lactation: contraindicated unless benefits outweigh potential fetal or infant risks; discuss with specialist.
• Drug interactions: review patient medication list for agents that may potentiate cardiotoxicity or myelosuppression.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Idarubicina Sandoz may interact with other medicines, altering its efficacy or toxicity profile.

Major Interactions (Avoid)

• Doxorubicin or other anthracyclines: additive cardiotoxicity; concurrent use should be avoided.
• High‑dose cyclophosphamide: increased risk of severe myelosuppression.
• Trastuzumab: synergistic cardiac toxicity when combined.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole): may raise idarubicin plasma levels.
• CYP3A4 inducers (e.g., rifampin): may reduce therapeutic exposure.
• Anticoagulants (e.g., warfarin): enhanced bleeding risk due to platelet suppression.
• Granulocyte colony‑stimulating factors: may affect hematologic recovery; monitor counts.